Last reviewed · How we verify
Acute monocytic/monoblastic leukemia
Approved treatments
- Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute monocytic/monoblastic leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Acute monocytic/monoblastic leukemia treatment landscape brief
- Acute monocytic/monoblastic leukemia treatment updates RSS
Frequently asked questions about Acute monocytic/monoblastic leukemia
What drugs treat Acute monocytic/monoblastic leukemia?
Tracked treatments include Daunorubicin Hydrochloride, Daunorubicine.
What is the treatment for Acute monocytic/monoblastic leukemia?
Standard treatment for Acute monocytic/monoblastic leukemia includes Daunorubicin Hydrochloride, Daunorubicine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute monocytic/monoblastic leukemia patent cliff · Acute monocytic/monoblastic leukemia CI report
- Treatment: Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Treatment: Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing